Aurinia Pharmaceuticals Inc. (AUPH)
| Market Cap | 1.96B |
| Revenue (ttm) | 72.23M |
| Net Income (ttm) | -170.20M |
| Shares Out | 129.67M |
| EPS (ttm) | -1.22 |
| PE Ratio | n/a |
| Forward PE | 434.78 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,055,787 |
| Open | 14.85 |
| Previous Close | 14.65 |
| Day's Range | 14.12 - 15.77 |
| 52-Week Range | 9.72 - 33.97 |
| Beta | 0.69 |
| Analysts | Buy |
| Price Target | 31.56 (+108.7%) |
| Earnings Date | Feb 22, 2022 |
About AUPH
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for AUPH stock is "Buy." The 12-month stock price forecast is 31.56, which is an increase of 108.73% from the latest price.
News
My 3 Top Biopharma Stock Picks for 2022
These three stocks are poised for a major breakout in 2022.
Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the management team will participate in two upcoming virtual inve...
Aurinia's Voclosporin Shows favorable Risk/Benefit Profile Over 3 Years In Lupus Nephritis
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has posted topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of Lupkynis (voclosporin) for active lupus nep...
The 2 Nasdaq Biotech Stocks to Watch Thursday
The market is getting close to new highs again, but choppy performance is likely.
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Tr...
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course ...
Aurinia (AUPH) Stock Up on Potential Acquisition Rumors
Aurinia (AUPH) gains on rumors of a potential acquisition yet again. Reportedly, the company is being eyed by Novartis.
Why Aurinia Pharmaceuticals Stock Bolted Higher Today
Renewed buyout speculation has investors piling into this biotech stock today.
AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Shares Taking Off Today
Aurinia Pharma (AUPH) stock is on the rise Thursday as investors hold out hope for a takeover of the company by Novartis (NVS). The post AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Sh...
AUPH Stock: 13 Things to Know About Aurinia Pharma as Shares Crash Today
Aurinia Pharma (AUPH) stock is taking a beating on Monday following a filing with the SEC after markets closed on Friday. The post AUPH Stock: 13 Things to Know About Aurinia Pharma as Shares Crash Toda...
Here's Why Aurinia Pharmaceuticals Is Falling Today
The company's recently filed unlimited shelf registration statement is making shareholders queasy.
Why Aurinia Pharmaceuticals Stock Crashed in After-Hours Trading on Friday
A $250 mixed shelf offering isn't sitting well with the biotech's shareholders.
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation during the 2021 Jefferies ...
Is Bristol Myers Squibb's Reported Acquisition of Aurinia a Smart Move?
It could be.
Here's Why Bristol Myers Squibb Can't Miss Out on Aurinia Pharmaceuticals
The biopharma's takeover bid has failed to materialize after nearly two weeks. Here's what might be going on.
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Lags Revenue Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of -25.81% and -0.24%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals: Q3 Earnings Insights
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported its Q3 earnings results on Wednesday, November 3, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
VICTORIA, British Columbia--(BUSINESS WIRE)--AURINIA REPORTS THIRD QUARTER AND NINE MONTHS 2021 FINANCIAL RESULTS AND COMPANY UPDATES
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Trea...
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of auto...
Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that it will release its third quarter 2021 financial results on Wednesday, Novem...
Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of auto...
Aurinia (AUPH) Surges 6.6%: Is This an Indication of Further Gains?
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in th...
2 Biotech Stocks That Could Go Parabolic This Week
These stocks could soon take flight.
Why Aurinia Pharmaceuticals Stock Is Blasting Higher Today
The biotech is reportedly in buyout talks with Bristol Myers Squibb.